ATHE — Alterity Therapeutics Limited

Summary of Alterity Therapeutics Q2 2021 Earnings Call

1. Key Financial Results and Metrics

• Operating Loss: $8.6 million for the period.
• Net Operating Cash Outflow: $7.3 million.
• Cash Position: $35 million as of December 31, buoyed by a $35 million capital raise from institutional investors.
• Revenue: No revenue reported; however, a grant from the Michael J. Fox Foundation for nearly $500,000 was noted, expected to be recorded in full-year results.

2. Strategic Updates and Business Highlights

• Leadership Change: Dr. David Stamler appointed CEO, succeeding Geoffrey Kempler, who remains Chairman.
• ATH434 Development: Completed Phase I trials and preparing for Phase II studies, focusing on Multiple System Atrophy (MSA). A natural history study (bioMUSE) has been launched in collaboration with Vanderbilt University to inform trial design.
• Research Validation: New animal data presented at the American Neurological Association's meeting confirmed ATH434's efficacy in reducing alpha-synuclein pathology.
• PBT2 Development: A new license for PBT2 was granted to combat antimicrobial resistance, expanding its potential applications beyond neurodegenerative diseases.
• Patent Approval: A new patent covering over 150 novel compounds was granted, aimed at addressing neurodegenerative conditions.

3. Forward Guidance and Outlook

• Phase II Trial: Preparations for the Phase II trial of ATH434 are on track, with expectations to commence in the second half of the year.
• Research Publications: Anticipated peer-reviewed publications on ATH434's mechanism of action and animal studies later in the year.
• Market Potential: Significant interest in PBT2 for addressing antimicrobial resistance, with plans to seek non-dilutive funding for development.

4. Bad News, Challenges, or Points of Concern

• No Revenue Generation: As a development-stage company, Alterity continues to operate without revenue, relying on grants and capital raises.
• Regulatory Challenges: The absence of regulatory precedents for MSA trials presents challenges in trial design and patient selection.
• PBT2 Clinical Hold: Previous partial clinical hold by the FDA for Alzheimer's raises concerns about future trials for PBT2, necessitating careful planning to address prior feedback.

5. Notable Q&A Insights

• ATH434 Phase II Preparation: Progressing well, with ongoing manufacturing and preclinical work; European regulatory feedback is expected soon.
• Interest from Big Pharma: Ongoing discussions with large pharmaceutical companies regarding potential collaborations.
• Market Value of PBT2: While the market potential for PBT2 in combating antimicrobial resistance is significant, specific estimates are not yet available.
• Future Research: Plans to conduct mitochondrial-level studies to assess the impact of ATH434 on cellular energy production.

Overall, Alterity Therapeutics is making notable progress in its drug development efforts, particularly with ATH434 and PBT2, despite facing challenges typical of a development-stage biopharmaceutical company. The financial position remains stable, supported by recent capital raises and grants, while the company continues to seek validation and partnerships in the competitive biotech landscape.